Abstract
Recent sequencing reports provided huge amounts of actionable data about colorectal cancer (CRC) genomic landscape for various purposes including diagnosis and prediction of prognosis and response to treatments. Next-generation sequencing (NGS) tests enable refinement of the selection of CRC patients to benefit from recent targeted therapies. These advances constitute a rationale for the emerging targeted therapies that are changing the patients’ outcomes. Notably, the advent of flexible next-generation sequencing (NGS) that allows multigene analysis is transforming our understanding of CRC. NGS workflow has successfully used to offer personalized medical care in CRC with a remarkable reduction of cost and time. However, this field is still facing many challenges regarding data analysis and development of bioinformatic tools as well as the clinical impact of the data obtained.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ålgars A, Sundström J, Lintunen M et al (2017) EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. Int J Cancer 140(4):922–929. https://doi.org/10.1002/ijc.30507
Bachet JB, Bouché O, Taieb J et al (2018) RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol 29:1211. https://doi.org/10.1093/annonc/mdy061
Belardinilli F, Capalbo C, Buffone A et al (2015) Validation of the ion torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. Clin Biochem 48(13–14):908–910. https://doi.org/10.1016/j.clinbiochem.2015.04.003
Benavides M, DĂaz-Rubio E, Carrato A et al (2019) Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials [published correction appears in ESMO Open. 2020 Jan;5(1)]. ESMO Open 4(6):e000599. https://doi.org/10.1136/esmoopen-2019-000599
Blakely AM, Lafaro KJ, Eng OS et al (2020) The association of tumor laterality and survival after cytoreduction for colorectal carcinomatosis. J Surg Res 248:20–27. https://doi.org/10.1016/j.jss.2019.10.001
Bylsma LC, Gillezeau C, Garawin TA et al (2020) Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis. Cancer Med 9(3):1044–1057. https://doi.org/10.1002/cam4.2747
Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9(1):34. https://doi.org/10.1186/s13073-017-0424-2
Cheng DT, Mitchell TN, Zehir A et al (2015) Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17(3):251–264. https://doi.org/10.1016/j.jmoldx.2014.12.006
Chevrier S, Arnould L, Ghiringhelli F et al (2014) Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations. Int J Oncol 45(3):1167–1174. https://doi.org/10.3892/ijo.2014.2528
Chibaudel B, André T, Tournigand C et al (2020) Understanding the prognostic value of primary tumor location and KRAS in metastatic colorectal cancer. A post-hoc analysis of the OPTIMOX3 DREAM phase III study. Clin Colorectal Cancer. https://doi.org/10.1016/j.clcc.2020.02.012
Ciardiello F, Normanno N, Maiello E et al (2014) Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 25(9):1756–1761. https://doi.org/10.1093/annonc/mdu230
Ciardiello F, Normanno N, Martinelli E et al (2016) Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 27(6):1055–1061. https://doi.org/10.1093/annonc/mdw136
Cohen R, Rousseau B, Vidal J, Colle R, Diaz LA Jr, André T (2020) Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond. Target Oncol 15(1):11–24. https://doi.org/10.1007/s11523-019-00690-0
Darwanto A, Hein AM, Strauss S et al (2017) Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform. BMC Cancer 17(1):358. https://doi.org/10.1186/s12885-017-3328-z
De Macedo MP, de Lima LG, Begnami MD et al (2014) KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations ? Exp Mol Pathol 96(2):257–260. https://doi.org/10.1016/j.yexmp.2014.02.014
Deenen MJ, Tol J, Burylo AM et al (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17(10):3455–3468. https://doi.org/10.1158/1078-0432.CCR-10-2209
Del Vecchio F, Mastroiaco V, Di Marco A et al (2017) Next-generation sequencing: recent applications to the analysis of colorectal cancer. J Transl Med 15:246. https://doi.org/10.1186/s12967-017-1353-y
D’Haene N, Le Mercier M, De Nève N et al (2015) Clinical validation of targeted next generation sequencing for colon and lung cancers. PLoS One 10(9):e0138245. https://doi.org/10.1371/journal.pone.0138245
Domingo E, Camps C, Kaisaki PJ et al (2018) Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol 3(9):635–643. https://doi.org/10.1016/S2468-1253(18)30117-1
Fabrizio DA, George TJ Jr, Dunne RF et al (2018) Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol 9(4):610–617. https://doi.org/10.21037/jgo.2018.05.06
Haley L, Tseng LH, Zheng G et al (2015) Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Mod Pathol 28(10):1390–1399. https://doi.org/10.1038/modpathol.2015.86
Hampel H, Pearlman R, Beightol M et al (2018) Assessment of tumor sequencing as a replacement for lynch syndrome screening and current molecular tests for patients with colorectal cancer. JAMA Oncol 4:806. https://doi.org/10.1001/jamaoncol.2018.0104
Han S-W, Kim H-P, Shin J-Y et al (2013) Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 8(5):e64271. https://doi.org/10.1371/journal.pone.0064271
Hempelmann JA, Scroggins SM, Pritchard CC et al (2015) MSIplus for integrated colorectal cancer molecular testing by next-generation sequencing. J Mol Diagn 17(6):705–714. https://doi.org/10.1016/j.jmoldx.2015.05.008
Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V (2017) The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87–98. https://doi.org/10.1016/j.ejca.2016.10.007
Hu Z, Ding J, Ma Z et al (2019) Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet 51(7):1113–1122. https://doi.org/10.1038/s41588-019-0423-x
Innocenti F, Ou FS, Qu X et al (2019) Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol 37(14):1217–1227. https://doi.org/10.1200/JCO.18.01798
Jørgensen JT (2015) Companion diagnostics: the key to personalized medicine. Foreword. Expert Rev Mol Diagn 15(2):153–156. https://doi.org/10.1586/14737159.2015.1002470
Khotskaya YB, Mills GB, Mills Shaw KR (2017) Next-generation sequencing and result interpretation in clinical oncology: challenges of personalized cancer therapy. Annu Rev Med 68:113–125. https://doi.org/10.1146/annurev-med-102115-021556
Kim JY, Kronbichler A, Eisenhut M et al (2019) Tumor mutational burden and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel) 11(11):1798. https://doi.org/10.3390/cancers11111798
Kothari N, Schell MJ, Teer JK et al (2014) Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol 67(9):764–767
LaDuca H, Stuenkel AJ, Dolinsky JS, Keiles S, Tandy S, Pesaran T et al (2014) Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients. Genet Med 16(11):830–837. https://doi.org/10.1038/gim.2014.40
Lee JM, Han YD, Cho MS et al (2019) Impact of tumor sidedness on survival and recurrence patterns in colon cancer patients. Ann Surg Treat Res 96(6):296–304. https://doi.org/10.4174/astr.2019.96.6.296
Li Q, Liu Y, Zhang H-M et al (2014) Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. Gastroenterol Res Pract 2014:827989. https://doi.org/10.1155/2014/827989
Lin PS, Semrad TJ (2018) Molecular testing for the treatment of advanced colorectal cancer: an overview. Methods Mol Biol 1765:281–297. https://doi.org/10.1007/978-1-4939-7765-9_18
Loree JM, Kopetz S, Raghav KP (2017) Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol 8(1):199–212. https://doi.org/10.21037/jgo.2017.01.01
Loree JM, Pereira AAL, Lam M et al (2018) Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res 24(5):1062–1072. https://doi.org/10.1158/1078-0432.CCR-17-2484
Luchini C, Bibeau F, Ligtenberg MJL et al (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30(8):1232–1243. https://doi.org/10.1093/annonc/mdz116
Lupini L, Bassi C, Mlcochova J et al (2015) Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer 15:808. https://doi.org/10.1186/s12885-015-1752-5
Ma W, Brodie S, Agersborg S et al (2017) Significant improvement in detecting BRAF, KRAS, and EGFR mutations using next-generation sequencing as compared with FDA-cleared kits. Mol Diagn Ther 21(5):571–579. https://doi.org/10.1007/s40291-017-0290-z
Malapelle U, Vigliar E, Sgariglia R et al (2015) Ion torrent next-generation sequencing for routine identification of clinically relevant mutations in colorectal cancer patients. J Clin Pathol 68(1):64–68. https://doi.org/10.1136/jclinpath-2014-202691
Malapelle U, Pisapia P, Sgariglia R et al (2016) Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. J Clin Pathol 69(9):767–771. https://doi.org/10.1136/jclinpath-2015-203403
McLeod HL, Sargent DJ, Marsh S et al (2010) Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from north American gastrointestinal intergroup trial N9741. J Clin Oncol 28(20):3227–3233. https://doi.org/10.1200/JCO.2009.21.7943
Morganti S, Tarantino P, Ferraro E et al (2019) Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol 133:171–182. https://doi.org/10.1016/j.critrevonc.2018.11.008
Nowak JA, Yurgelun MB, Bruce JL et al (2017) Detection of mismatch repair deficiency and microsatellite instability in colorectal adenocarcinoma by targeted next-generation sequencing. J Mol Diagn 19(1):84–91. https://doi.org/10.1016/j.jmoldx.2016.07.010
Papaxoinis G, Kotoula V, Giannoulatou E et al (2018) Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Med Oncol 35(7):101. https://doi.org/10.1007/s12032-018-1160-1
Peeters M, Oliner KS, Parker A et al (2013) Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19(7):1902–1912. https://doi.org/10.1158/1078-0432.CCR-12-1913
Petrelli F, Tomasello G, Borgonovo K et al (2017) Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 3(2):211–219. https://doi.org/10.1001/jamaoncol.2016.4227
Piawah S, Venook AP (2019) Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer 125(23):4139–4147. https://doi.org/10.1002/cncr.32163
Price TJ, Tang M, Gibbs P et al (2018) Targeted therapy for metastatic colorectal cancer. Expert Rev Anticancer Ther 18(10):991–1006. https://doi.org/10.1080/14737140.2018.1502664
Pritchard CC, Smith C, Salipante SJ et al (2012) ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 14(4):357–366. https://doi.org/10.1016/j.jmoldx.2012.03.002
Rohlin A, Rambech E, Kvist A et al (2017) Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing. Familial Cancer 16(2):195–203. https://doi.org/10.1007/s10689-016-9934-0
Roy-Chowdhuri S, Pisapia P, Salto-Tellez M et al (2019) Invited review-next-generation sequencing: a modern tool in cytopathology. Virchows Arch 475:3. https://doi.org/10.1007/s00428-019-02559-z
Salem ME, Battaglin F, Goldberg RM et al (2019) Molecular analyses of left- and right-sided tumors in adolescents and young adults with colorectal cancer [published online ahead of print, 2019 Dec 17]. Oncologist 25:404–413. https://doi.org/10.1634/theoncologist.2019-0552
Sandhu J, Lavingia V, Fakih M (2019) Systemic treatment for metastatic colorectal cancer in the era of precision medicine. J Surg Oncol 119(5):564–582. https://doi.org/10.1002/jso.25421
Sapari NS, Elahi E, Wu M et al (2014) Feasibility of low-throughput next generation sequencing for germline DNA screening. Clin Chem 60(12):1549–1557. https://doi.org/10.1373/clinchem.2014.227728
Schrock AB, Ouyang C, Sandhu J et al (2019) Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol 30(7):1096–1103. https://doi.org/10.1093/annonc/mdz134
Seymour MT, Brown SR, Middleton G et al (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 14(8):749–759. https://doi.org/10.1016/S1470-2045(13)70163-3
Shimada Y, Kameyama H, Nagahashi M et al (2017) Comprehensive genomic sequencing detects important genetic differences between right-sided and left-sided colorectal cancer. Oncotarget 8(55):93567–93579. https://doi.org/10.18632/oncotarget.20510
Singh RR, Patel KP, Routbort MJ et al (2013) Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 15(5):607–622. https://doi.org/10.1016/j.jmoldx.2013.05.003
Stadler ZK, Battaglin F, Middha S et al (2016) Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels. J Clin Oncol 34(18):2141–2147. https://doi.org/10.1200/JCO.2015.65.1067
Sunakawa Y, Ichikawa W, Tsuji A et al (2017) Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06 trials. Clin Colorectal Cancer 16(3):e171–e180. https://doi.org/10.1016/j.clcc.2016.09.010
Sunakawa Y, Mogushi K, Lenz HJ et al (2018) Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer. Mol Cancer Ther 17(12):2788–2795. https://doi.org/10.1158/1535-7163.MCT-18-0694
Tafe LJ (2015) Targeted next-generation sequencing for hereditary cancer syndromes: a focus on lynch syndrome and associated endometrial cancer. J Mol Diagn 17(5):472–482. https://doi.org/10.1016/j.jmoldx.2015.06.001
Talseth-Palmer BA, Bauer DC, Sjursen W et al (2016) Targeted next-generation sequencing of 22 mismatch repair genes identifies lynch syndrome families. Cancer Med 5(5):929–941. https://doi.org/10.1002/cam4.628
Tejpar S, Stintzing S, Ciardiello F et al (2017) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials [published correction appears in JAMA Oncol. 2017 Dec 1;3(12):1742]. JAMA Oncol 3(2):194–201. https://doi.org/10.1001/jamaoncol.2016.3797
Timmermann B, Kerick M, Roehr C et al (2010) Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 5(12):e15661. https://doi.org/10.1371/journal.pone.0015661
Udar N, Lofton-Day C, Dong J et al (2018) Clinical validation of the next-generation sequencing-based extended RAS panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study. J Cancer Res Clin Oncol 144(10):2001–2010. https://doi.org/10.1007/s00432-018-2688-3
Valle L, Vilar E, Tavtigian SV, Stoffel EM (2019) Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol 247(5):574–588. https://doi.org/10.1002/path.5229
von Einem JC, Heinemann V, von Weikersthal LF et al (2014) Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 140(9):1607–1614. https://doi.org/10.1007/s00432-014-1678-3
Wu Y, Xu J, Du C et al (2019) The predictive value of tumor mutation burden on efficacy of immune checkpoint inhibitors in cancers: a systematic review and meta-analysis. Front Oncol 9:1161. https://doi.org/10.3389/fonc.2019.01161
Wu CC, Wang JH, Lin PC et al (2020) Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: a network meta-analysis. Crit Rev Oncol Hematol 145:102823. https://doi.org/10.1016/j.critrevonc.2019.102823
Zhang L, Chen L, Sah S et al (2014) Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist 19(4):336–343. https://doi.org/10.1634/theoncologist.2013-0180
Zihui Yong Z, Ching GTH, Ching MTC (2020) Metastatic profile of colorectal cancer: interplay between primary tumor location and KRAS status. J Surg Res 246:325–334. https://doi.org/10.1016/j.jss.2018.11.025
Authors’ Contribution
KE wrote the chapter and SA supervised the writing process.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
El Bairi, K., Afqir, S. (2020). Next-Generation Sequencing for Colorectal Cancer Management. In: El Bairi, K. (eds) Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. Springer, Cham. https://doi.org/10.1007/978-3-030-53821-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-53821-7_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-53820-0
Online ISBN: 978-3-030-53821-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)